- Home
- SNBR vs ERAS Comparison
SNBR vs ERAS Comparison
Compare SNBR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- ERAS
- Stock Information
- Founded
- SNBR 1987
- ERAS 2018
- Country
- SNBR United States
- ERAS United States
- Employees
- SNBR N/A
- ERAS N/A
- Industry
- SNBR Home Furnishings
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- SNBR Consumer Discretionary
- ERAS Health Care
- Exchange
- SNBR Nasdaq
- ERAS Nasdaq
- Market Cap
- SNBR 399.8M
- ERAS 432.6M
- IPO Year
- SNBR 1998
- ERAS 2021
- Fundamental
- Price
- SNBR $6.86
- ERAS $1.23
- Analyst Decision
- SNBR Hold
- ERAS Strong Buy
- Analyst Count
- SNBR 3
- ERAS 6
- Target Price
- SNBR $12.00
- ERAS $4.83
- AVG Volume (30 Days)
- SNBR 1.1M
- ERAS 1.8M
- Earning Date
- SNBR 03-05-2025
- ERAS 03-20-2025
- Dividend Yield
- SNBR N/A
- ERAS N/A
- EPS Growth
- SNBR N/A
- ERAS N/A
- EPS
- SNBR N/A
- ERAS N/A
- Revenue
- SNBR $1,682,296,000.00
- ERAS N/A
- Revenue This Year
- SNBR $4.50
- ERAS N/A
- Revenue Next Year
- SNBR $3.07
- ERAS N/A
- P/E Ratio
- SNBR N/A
- ERAS N/A
- Revenue Growth
- SNBR N/A
- ERAS N/A
- 52 Week Low
- SNBR $5.94
- ERAS $1.20
- 52 Week High
- SNBR $20.75
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- SNBR 35.45
- ERAS 39.36
- Support Level
- SNBR $5.94
- ERAS $1.40
- Resistance Level
- SNBR $6.79
- ERAS $1.61
- Average True Range (ATR)
- SNBR 0.67
- ERAS 0.11
- MACD
- SNBR 0.29
- ERAS 0.01
- Stochastic Oscillator
- SNBR 58.60
- ERAS 4.00
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.